Stock Track | LifeTech Scientific Soars 5.36% Intraday on Strong 2025 Annual Results with Adjusted Net Profit Up 24.9%

Stock Track
Apr 01

LifeTech Scientific Corporation's stock surged 5.36% during intraday trading on Wednesday, following the release of its robust annual financial results for 2025.

The medical device company reported steady revenue growth of approximately 5.1% year-on-year to RMB1,369.8 million, driven by a 19.9% increase in stent graft sales. Notably, the company's adjusted net profit saw a significant increase of approximately 24.9% to RMB353.4 million, while its gross profit margin remained strong at 74.4%.

The positive performance was supported by considerable growth in overseas markets, particularly in Europe where sales grew by approximately 25.9%, making it the Group's largest overseas market. The company also maintained a strong cash position and continued its commitment to innovation, with R&D investment accounting for about 24.0% of total revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10